Cargando…

Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer

Enzalutamide is the first second-generation nonsteroidal androgen receptor (AR) antagonist with a strong binding affinity to AR. Most significantly, enzalutamide can prolong not only overall survival time and metastatic free survival time for patients with lethal castration-resistant prostate cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rajaram, Pravien, Rivera, Alyssa, Muthima, Kevin, Olveda, Nicholas, Muchalski, Hubert, Chen, Qiao-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287767/ https://www.ncbi.nlm.nih.gov/pubmed/32456317 http://dx.doi.org/10.3390/molecules25102448

Ejemplares similares

Second generation androgen receptor antagonists and challenges in prostate cancer treatment
por: Chen, Yanhua, et al.
Publicado: (2022)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.
por: Jungwirth, A., et al.
Publicado: (1997)

Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer
por: Culig, Zoran
Publicado: (2021)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

Second generation androgen receptor antagonist, TQB3720 abrogates prostate cancer growth via AR/GPX4 axis activated ferroptosis
por: Zhang, Zhongqing, et al.
Publicado: (2023)

A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2017)

Hormones and prostate carcinogenesis: Androgens and estrogens
por: Bosland, Maarten C., et al.
Publicado: (2011)

Trends in the Use of Second-Generation Androgen Receptor Axis Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer and Clinical Factors Predicting Biological Recurrence
por: Nakane, Keita, et al.
Publicado: (2023)

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
por: Saad, Fred, et al.
Publicado: (2021)

Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis
por: Kunath, Frank, et al.
Publicado: (2015)

Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer
por: Kokal, Miriam, et al.
Publicado: (2020)

Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges
por: Kita, Yuki, et al.
Publicado: (2018)

Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors
por: Wefel, Jeffrey S., et al.
Publicado: (2022)

Brønsted acid-promoted azide–olefin [3 + 2] cycloadditions for the preparation of contiguous aminopolyols: The importance of disiloxane ring size to a diastereoselective, bidirectional approach to zwittermicin A
por: Muchalski, Hubert, et al.
Publicado: (2010)

The androgen-thyroid hormone crosstalk in prostate cancer and the clinical implications
por: Torabinejad, Sepehr, et al.
Publicado: (2023)

Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer
por: Han, G. Celine, et al.
Publicado: (2017)

Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer
por: Chung, Doo Yong, et al.
Publicado: (2021)

Small Molecule Antagonists of the Nuclear Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer
por: Johnson, James K., et al.
Publicado: (2016)

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
por: Sugawara, Tatsuo, et al.
Publicado: (2019)

Influence of Androgen Receptor Antagonist MDV3100 Therapy on Rats With Benign Prostatic Hyperplasia
por: Yang, Minggen, et al.
Publicado: (2021)

Synthesis of Hydantoin Androgen Receptor Antagonists and Study on Their Antagonistic Activity
por: Ma, Longjun, et al.
Publicado: (2022)

Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL
por: Kashiwabara, Takeshi, et al.
Publicado: (2018)

Phosphorylation of the Androgen Receptor by PIM1 in Hormone Refractory Prostate Cancer
por: Ha, Susan, et al.
Publicado: (2012)

Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis
por: Chen, Xiangyu, et al.
Publicado: (2023)

P-Glycoprotein and Androgen Receptor Expression Reveals Independence of Canine Prostate Cancer from Androgen Hormone Stimulation
por: Cavalca, Alexandre Matheus Baesso, et al.
Publicado: (2022)

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer
por: Tovar, Christian, et al.
Publicado: (2011)

Antagonistic Functions of Androgen Receptor and NF-κB in Prostate Cancer—Experimental and Computational Analyses
por: Basílio, José, et al.
Publicado: (2022)

Cheminformatic Analysis and Machine Learning Modeling to Investigate Androgen Receptor Antagonists to Combat Prostate Cancer
por: Yu, Tianshi, et al.
Publicado: (2023)

Systems Pharmacology Modeling of Prostate‐Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down‐Regulator
por: Mistry, HB, et al.
Publicado: (2016)

A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer
por: Miki, Kenta, et al.
Publicado: (2016)

The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis
por: Zhang, Xianlu, et al.
Publicado: (2023)

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
por: Edwards, J, et al.
Publicado: (2003)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer
por: Merson, S, et al.
Publicado: (2014)

Androgen Receptor Imaging in the Management of Hormone-Dependent Cancers with Emphasis on Prostate Cancer
por: Kairemo, Kalevi, et al.
Publicado: (2023)

Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

SUN-139 Luminescence-Based Drug Screen for Novel Androgen Receptor Antagonists for Prostate Cancer Therapy
por: Azur, Romie Angelo G, et al.
Publicado: (2020)

H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer
por: Baratchian, Mehdi, et al.
Publicado: (2022)

Androgen receptor agonist and antagonist reduce response of cytokine‐induced killer cells on prostate cancer cells
por: Pungsrinont, Thanakorn, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qnbo3jkhgadac3m0nf4278fu6o